Players Needed to Solve Puzzles and Help Advance Cancer Research

The CRG and CNAG-CRG have launched GENIGMA, a videogame that enlists players to solve puzzles while generating real-world scientific data that can detect alterations in genomic sequences and ultimately advance breast cancer research.

The game, out today on iOS and Android and available in English, Spanish, Catalan and Italian, is the result of a two-and-a-half-year long citizen science project developed by a team of researchers at the Centre for Genomic Regulation (CRG), the Centro Nacional de Análisis Genómico (CNAG-CRG) and game professionals.

The game was created to boost worldwide research efforts that depend on cancer cell lines, a critical resource used by scientists to study cancer and test new drugs to treat the disease. One of the limitations of cancer cell lines are a lack of high-resolution genome reference maps, which are necessary to help researchers interpret their scientific results, for example pinpointing the location of genes of therapeutic interest or potential mutation sites.

"Cell lines are responsible for the discovery of vaccines, chemotherapies for cancer or IVF for infertility. This makes them a pillar of modern biology," explains ICREA Research Professor Marc A. Marti-Renom, with dual affiliation at the CRG and CNAG-CRG and whose research underpins GENIGMA. "However, the lack of genome reference maps limits current scientific progress. It's like asking people to navigate modern cities using maps from the past. With the help of other people, we can update these maps, which will allow us to make fast progress in breast cancer research."

Professor Marti-Renom's research group has developed methods to create genomic reference maps by visualising the genome in three-dimensional space. However, this requires significant time and resources to train artificial intelligence, as well as vast computational power.

The researchers launched GENIGMA because they believe that data generated by players could be a more effective method of updating the reference maps compared to using AI alone. The 'herd intelligence' of players can also provide creative solutions in ways that AI might not be able to.

To play GENIGMA, players have to solve a puzzle involving a string of blocks of different colours and shapes. Each string represents a genetic sequence in the cancer cell line, and how players organise the blocks is a potential solution to the location of genes.

Players have to reorganise the blocks so that they attain the highest-score possible. The higher the number of players and high scores, the higher likelihood that researchers have found the correct sequence for this particular location in the reference map.

"Anyone with a smartphone from anywhere in the world can download GENIGMA for free and make a direct contribution to research, lending their logic and dexterity to the service of science," says Elisabetta Broglio, citizen science facilitator at the CRG. "GENIGMA will analyze the solutions provided by the players as a collective and not as individuals, and will take advantage of creative solutions impossible to find with deterministic algorithms."

The first genome reference map researchers will attempt to solve is for the T-47D breast cancer cell line, one of the most commonly used resources in cancer research. GENIGMA's research team estimate that 30 thousand players solving an average of 50 games each would generate enough data to reveal the reference map of the 20.000 genes in this breast cancer cell line.

The game launches today with a three-month long campaign - the #GenigmaChallenge. Every week on Monday, for a total period of three months, the GENIGMA team will introduce new genome fragments from the T-47D cell line to be arranged by players. The first genome fragments needing to be arranged are from chromosome 17, which contain a high number of breast cancer related genes. This includes BRCA1, for which mutations have been associated with about 40% of inherited breast cancer.

GENIGMA was developed over two and a half years, involving more than 500 people across 13 workshops. The game was conceived and tested by a diverse group of people from different backgrounds, including researchers, students, teachers, artists, medical professionals, bioethicists, journalists, representatives from patient organisations, artists and game developers.

According to Oriol Ripoll, Creative at JOCS al SEGON and Coordinator of GENIGMA's game design team, "Science can often feel inaccessible for most people, which is why being able to pick up your phone to play GENIGMA is so exciting. Not only can you combine the universal appeal and popularity of videogames to contribute towards advancing medical research, you will also learn more about science."

GENIGMA is funded by ORION, a 4-year project that has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 741527. This project addresses the Horizon 2020 call for "SwafS-04-2016" under the Science with and for Society Work Programme. GENIGMA is also a result of a collaboration with the 'Fondazione ANT Italia Onlus' and Arima Genomics.

For further information, please visit:
ORION Project, https://www.orion-openscience.eu
GENIGMA Game, https://genigmagame.app/en/

Most Popular Now

Stepping Hill Hospital Announced as SPAR…

Stepping Hill Hospital, part of Stockport NHS Foundation Trust, has replaced its bedside units with state-of-the art devices running a full range of information, engagement, communications and productivity apps, to...

DMEA 2025: Digital Health Worldwide in B…

8 - 10 April 2025, Berlin, Germany. From the AI Act, to the potential of the European Health Data Space, to the power of patient data in Scandinavia - DMEA 2025...

Is AI in Medicine Playing Fair?

As artificial intelligence (AI) rapidly integrates into health care, a new study by researchers at the Icahn School of Medicine at Mount Sinai reveals that all generative AI models may...

New System for the Early Detection of Au…

A team from the Human-Tech Institute-Universitat Politècnica de València has developed a new system for the early detection of Autism Spectrum Disorder (ASD) using virtual reality and artificial intelligence. The...

Generative AI's Diagnostic Capabili…

The use of generative AI for diagnostics has attracted attention in the medical field and many research papers have been published on this topic. However, because the evaluation criteria were...

Diagnoses and Treatment Recommendations …

A new study led by Prof. Dan Zeltzer, a digital health expert from the Berglas School of Economics at Tel Aviv University, compared the quality of diagnostic and treatment recommendations...

AI Tool can Track Effectiveness of Multi…

A new artificial intelligence (AI) tool that can help interpret and assess how well treatments are working for patients with multiple sclerosis (MS) has been developed by UCL researchers. AI uses...

Surrey and Sussex Healthcare NHS Trust g…

Surrey and Sussex Healthcare NHS Trust has marked an important milestone in connecting busy radiologists across large parts of South East England, following the successful go live of Sectra's enterprise...

Dr Jason Broch Joins the Highland Market…

The Highland Marketing advisory board has welcomed a new member - Dr Jason Broch, a GP and director with a strong track record in the NHS and IT-enabled transformation. Dr Broch...

DMEA 2025 Ends with Record Attendance an…

8 - 10 April 2025, Berlin, Germany. DMEA 2025 came to a successful close with record attendance and an impressive program. 20,500 participants attended Europe's leading digital health event over the...

Multi-Resistance in Bacteria Predicted b…

An AI model trained on large amounts of genetic data can predict whether bacteria will become antibiotic-resistant. The new study shows that antibiotic resistance is more easily transmitted between genetically...

AI-Driven Smart Devices to Transform Hea…

AI-powered, internet-connected medical devices have the potential to revolutionise healthcare by enabling early disease detection, real-time patient monitoring, and personalised treatments, a new study suggests. They are already saving lives...